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Among the opioid receptors, the κ-opioid receptor (κOR) has been
gaining considerable attention as a potential therapeutic target
for the treatment of complex CNS disorders including depression,
visceral pain, and cocaine addiction. With an interest in discover-
ing novel ligands targeting κOR, we searched natural products for
unusual scaffolds and identified collybolide (Colly), a nonnitroge-
nous sesquiterpene from the mushroom Collybia maculata. This
compound has a furyl-δ-lactone core similar to that of Salvinorin
A (Sal A), another natural product from the plant Salvia divinorum.
Characterization of the molecular pharmacological properties re-
veals that Colly, like Sal A, is a highly potent and selective κOR
agonist. However, the two compounds differ in certain signaling
and behavioral properties. Colly exhibits 10- to 50-fold higher po-
tency in activating the mitogen-activated protein kinase pathway
compared with Sal A. Taken with the fact that the two compounds
are equipotent for inhibiting adenylyl cyclase activity, these re-
sults suggest that Colly behaves as a biased agonist of κOR. Be-
havioral studies also support the biased agonistic activity of Colly
in that it exhibits ∼10-fold higher potency in blocking non–hista-
mine-mediated itch compared with Sal A, and this difference is not
seen in pain attenuation by these two compounds. These results
represent a rare example of functional selectivity by two natural
products that act on the same receptor. The biased agonistic ac-
tivity, along with an easily modifiable structure compared with Sal
A, makes Colly an ideal candidate for the development of novel
therapeutics targeting κOR with reduced side effects.
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Opioid receptors, members of family A of G-protein–coupledreceptors (GPCRs), and their ligands have been extensively
studied for their involvement in analgesia and sedation (1, 2).
Among the different subtypes of opioid receptors, the κ opioid
receptor (κOR) displays a repertoire of physiological actions dis-
tinct from μ (μOR) and δ (δOR) receptors (3). κOR activation
leads to antinociception without the side effects associated with
μOR activation such as physical dependence, respiratory de-
pression, or inhibition of gastrointestinal transit (4, 5). In addition,
κOR agonists have antipruritic effects and can block the effects of
psychostimulants (6–8). Thus, κOR agonists could be potential
therapeutics to treat addiction, visceral pain, pruritus, or pain
killers with low abuse potential (9–12). However, in vivo κOR
activation is associated with side effects like anxiety, stress, di-
uresis, dysphoria/aversion, and psychomimetic effects (6–8). Also,
activation of the κOR system has been implicated in relapse to
drugs of abuse; this limits the use of κOR agonists in the treatment
of drug addiction (13, 14). Studies correlating the dysphoric effects
of κOR agonists to the G-protein–independent activation of the
p38 MAPK pathway (8, 13, 15) suggest that identification of κOR
agonists biased to G-protein–mediated signaling could lead to the
development of therapeutics with reduced side effects. This sug-
gestion has spurred the search for novel κOR ligands or scaffolds
that could provide novel treatment strategies for a variety of dis-
orders where κOR involvement has been implicated (16, 17).
Previously identified synthetic κOR ligands were mostly ni-
trogenous compounds with a tertiary amine group (16). However,
about a decade ago, Salvinorin A (Sal A), a nonnitrogenous
diterpene extracted from the Mexican mint Salvia divinorum and
characterized by the presence of a furyl-δ-lactone motif (Fig. 1),
was identified as a potent and highly selective κOR agonist (18).
The structural novelty of Sal A led to extensive structure–activity
relationship (SAR) studies through hemisynthetic approaches
(19). The furyl-δ-lactone group of Sal A (Fig. 1; motif highlighted
in red) is present in other members of the terpene families (20)
and appears as a highly oxygenated motif in the diterpene scaffold
that is involved in ligand binding to κOR in conjunction with other
oxygenated groups (esters) in the molecule.
In this study, we focused on the sesquiterpene Colly and its
diastereoisomer 9-epi-Colly, extracted from the fungus Collybia
maculata, because they represent the first examples, to our
knowledge, of sesquiterpene structures with the furyl-δ-lactone
motif (21). For molecular pharmacological characterization, we
used heterologous cells individually expressing the three human
opioid receptor types and show that Colly and 9-epi-Colly function
as selective and potent κOR agonists. Furthermore, we show that,
although Colly and Sal A activate some signal transduction
pathways to the same extent and have comparable behavior effects
in some assays, they exhibit substantial differences in other path-
ways and behavioral assays suggesting biased agonism. Finally,
taken with our finding that Colly exhibits potent antipruritic
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activities, these results demonstrate that Collys represent a novel
class of κOR-selective agonists that could be used for further ex-
plorations of the molecular pharmacology and functioning of this
important therapeutic target.
Results
Collybolides Exhibit Structural Similarity to Sal A. Colly and 9-epi-
Colly share the common furyl-δ-lactone motif (i.e., a δ-lactone
with its Cδ carbon substituted by the furyl group) present in Sal A
(Fig. 1). A bicyclic core with rings A (cyclohexane) and B (δ-lac-
tone) is a common feature of these terpene compounds. Colly has
a trans-ring A/B junction, as in Sal A, whereas 9-epi-Colly has a cis
junction. Besides the δ-lactone, the central ring A is substituted by
an additional ring, a highly oxygenated cyclohexane with two es-
ters and a ketone in Sal A, and a γ-lactone in the Collys. In
contrast to Sal A, Collys have a bulky C-6 benzoyl ester in ring B
(Fig. 1). In this study, we report the absolute configurations of
both sesquiterpenes using single crystal X-ray diffraction analysis
in the absence of any chemical transformation (SI Materials and
Methods) and establish the epimeric nature of Colly and 9-epi-
Colly at the level of C-9 (Fig. 1). Interestingly, the absolute con-
figuration of the asymmetric Cδ carbon (furyl-bearing carbon) in
the δ-lactone (Fig. 1) is inverse in Sal A and Collys. The presence
of the furyl-δ-lactone motif in Collys, as well as their novel ste-
reochemical features led us to examine whether they could func-
tion as κOR selective agonists.
Collybolides Exhibit High Affinity Binding to Human κOR. Ligand
binding assays using whole cells or membrane preparations
expressing human κOR (hκOR) and [3H]Naloxone, a non-
selective opioid receptor antagonist, as the radiolabeled ligand
show that Colly exhibits a dose-dependent displacement profile
with a Ki ∼10−10 M in membrane preparations (Fig. 2 and Table
S1) and ∼10−7 M in whole cells (Fig. S1). Sal A, the synthetic
κOR agonist U69,593, and the peptidic κOR agonist dynorphin
A8 (Dyn A8) displace [3H]Naloxone binding with affinities in the
nanomolar range (Ki ∼ 1–7 × 10−9 M) in membrane preparations
(Table S1), and 10−8–10−9 M in whole cells (Table S2). In-
terestingly, epimerization at position 9 (9-epi-Colly) decreases
the ability of the compound to displace [3H]Naloxone binding to
hκOR (Fig. 2, Table S1, and Fig. S1). The displacement profile
of receptor-bound [3H]Naloxone by Colly and 9-epi-Colly is not
probe specific or dependent on the assay buffer conditions used,
because a similar profile is seen with [3H]Diprenorphine or
[3H]U69,593 or when using different assay buffer conditions (Fig.
2, Table S1, and Fig. S1). Together these results indicate that
Collys bind to hκOR.
Collybolides Exhibit Selectivity to hκOR. We examined the selec-
tivity of Collys for hκOR by comparing their ability to displace
[3H]Naloxone binding to hμOR or hδOR and to signal through
these receptors. We find that neither Colly nor 9-epi-Colly dis-
place [3H]Naloxone binding to hμOR or hδOR (Fig. 3). Also,
Collys do not elicit changes in [35S]GTPγS binding or ERK1/2
phosphorylation in cells expressing hμOR or hδOR (Fig. S2) nor
do they block DAMGO (μOR agonist) or deltorphin II (δOR)-
mediated increases in phospho ERK1/2 (Fig. S2). These results
indicate that Collys exhibit selectivity toward hκOR. This selec-
tivity is supported by the ability of Colly to displace [3H]Naloxone
binding to membranes from WT mice but not from mice lacking
κOR (Fig. 3 and Fig. S3).
Collybolide Is a High Affinity Agonist of hκOR. Next we examined
signaling by Colly using [35S]GTPγS binding assays. Colly dose-
dependently increases [35S]GTPγS binding with an EC50 of
∼10−9 M (Fig. 4A), a potency similar to that of 9-epi-Colly, Sal A,
U69,593, and Dyn A8 (Fig. 4A and Table 1). Interestingly, 9-epi-
Colly exhibits substantial lower efficacy suggesting partial ago-
nism (Fig. 4A). The increase in [35S]GTPγS binding mediated by
both Collys is blocked by a κOR antagonist, nor-BNI (Fig. 4B).
Moreover, Colly dose-dependently increases [35S]GTPγS binding
to WT but not κOR KO membranes (Fig. 4C), supporting Collys
as κOR selective agonists.
Because κOR activation leads to inhibition of adenylyl cyclase
activity and consequently decreases in cAMP levels (22), we
examined effects of Colly on adenylyl cyclase activity. We find
that Colly dose-dependently decreases adenylyl cyclase ac-
tivity with a nanomolar potency comparable to that of Sal A
(Fig. 4D and Table 1) but markedly lower than that of 9-epi-Colly
that exhibits a potency in the micromolar range (Table 1). To-
gether these results indicate that Collys exhibit agonistic activity
at hκOR.
Fig. 1. Structures of salvinorin A, collybolide, and 9-epi-collybolide. Chemical
structures of the naturally occurring Sal A (from the Mexican mint S. divinorum)
and of collybolide and 9-epi-collybolide (from the fungus C. maculata)
shown with the common furyl-δ-lactone motif highlighted in red. The ab-
solute configurations of collybolide (2R,4R,5S,6R,7S,9R) and 9-epi-col-
lybolide (2R,4R,5S,6R,7S,9S) were determined by the Bijvoet’s method
using the oxygen atoms as anomalous scattering centers (SI Materials
and Methods).
Fig. 2. Displacement of radiolabeled ligand binding to human κOR. Mem-
branes (200 μg) from HEK-293 cells expressing hκOR were incubated with
[3H]Naloxone (Nal), [3H]Diprenorphine (Dip), or [3H]U69,493 (U69) (3 nM) in
50 mM Tris·Cl, pH 7.8, containing 1 mM EGTA, 5 mM MgCl2, and protease
inhibitor mixture in the absence or presence of Colly (Col), 9-epi-Colly (9-epi-
Col), or Sal A (10−13–10−5 M). Values at 10−13 M cold ligand were taken as
100%. Data represent mean ± SEM; n = 6.
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Collybolide Induces Robust Endocytosis of hκOR. Because treatment
with agonists can induce rapid and robust internalization of
hκOR (23), we examined the ability of Colly to induce κOR
endocytosis. A time course analysis reveals rapid and robust
endocytosis (Fig. S4), and the dose–response analysis reveals an
EC50 for Colly ∼5 × 10−10 M that is comparable to that of Sal A
and much greater than that of 9-epi-Colly (Fig. 4E and Table 1).
These results show that Colly, like other high potency hκOR
agonists, induces rapid and robust receptor internalization.
Collybolide Exhibits Biased Agonism at hκOR. Next, we examined
the ability of Collys to induce ERK1/2 phosphorylation. We find
that Collys exhibit peak ERK1/2 phosphorylation at ∼3–5 min
(Fig. S5). Interestingly, Colly exhibits an inverted “U-shape”
profile with maximal stimulation at ∼10−9 M; at higher concen-
trations, Colly-mediated signaling is rapidly desensitizing both in
HEK or CHO cells expressing hκOR (Fig. 4F and Fig. S5). In
contrast, Sal A (like 9-epi-Colly and U69,593) exhibits a sig-
moidal dose–response curve with maximal ERK1/2 phosphory-
lation at ∼10−7–10−6 M (Fig. 4F and Table 1). To ascertain
whether the inverted U-shaped profile for ERK1/2 phosphory-
lation by Colly is also seen with other signaling pathways, we
examined the profile for phosphorylation of Akt at S473 and at
T308. We find that Colly exhibits a sigmoidal dose (and not an
inverted U-shaped) response curve for Akt both at S473 and
T308 (Fig. 4 G and H). Interestingly, Colly appears to be more
efficacious than Sal A at phosphorylating Akt at both sites
(Table 1). These observations suggest that Colly exhibits differ-
ences in signaling from Sal A at hκOR.
Collybolide Exhibits κOR Agonist Activity in Mice. Next, we focused
on Colly and evaluated its behavioral effects in mice. We find
that the antinociceptive activity of Colly is similar to that of Sal A
with peak activity at 20 min following drug administration (Fig.
5A). We did not find significant differences between Colly and
vehicle-treated controls in the forced swim test, although Colly-
treated mice tended to spend less time being immobile (Fig. 5B).
In the elevated plus maze test, Colly and Sal A did not exhibit
significant differences, although Colly-treated animals showed a
higher tendency to spend less time in the open arms (i.e., tend to
exhibit a higher level of anxiety), and this was blocked in animals
treated with nor-BNI (Fig. 5C). The effect of Colly in the con-
ditioned place preference/aversion assay shows that single daily
injections for 4 d leads to significant (*P < 0.05) conditioned
place aversion (Fig. 5D); this has been shown for κOR agonists
including Sal A (3, 24). In contrast to these assays where Colly
behaves in a manner similar to Sal A, Colly differs remarkably
from Sal A when examined for its ability to block pruritus (non–
histamine-mediated itch). Colly (2 mg/kg) significantly attenu-
ates chloroquine-mediated scratching behavior; this is not seen
with the same dose of Sal A (Fig. 5E). In addition, Colly ex-
hibits dose-dependent inhibition of pruritus with a high potency
Fig. 3. Collybolides bind to human κOR but not μOR or δOR. Membranes
(200 μg) from HEK-293 cells expressing hκOR, hδOR, or hμOR were incubated
with [3H]Naloxone (3 nM) in 50 mM Tris·Cl, pH 7.8, containing 1 mM EGTA,
5 mM MgCl2, and protease inhibitor mixture in the presence of collybolide
(A) or 9-epi-collybolide (B) (10−13–10−5 M). Data represent mean ± SEM; n = 6.
(C) Cerebral cortex membranes (100 μg) from WT or κOR KO mice (κOR k/o)
were incubated with [3H]Naloxone (3 nM) in the presence of collybolide
(10−13–10−5 M). Data represent mean ± SEM; n = 3 individual animals. Values
at 10−13 M cold ligand were taken as 100%. n.d., not detected.
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Fig. 4. Signaling by collybolides in membranes expressing hκOR. Mem-
branes (20 μg) from HEK-293 cells expressing hκOR were subjected to a
[35S]GTPγS binding assay in the presence of Colly (Col), 9-epi-Colly (9-epi-Col),
or Sal A (10−13–10−5 M) (A) without or with preincubation (30 min) with
nor-BNI (B). (C) [35S]GTPγS binding using cerebral cortex membranes from
WT and κOR KO mice and Col (10−13–10−5 M). (D) Membranes (2 μg) from
HEK-293 cells expressing hκOR were treated with Col or Sal A (10−13–10−5 M),
and cAMP levels were measured. Values (A–D) at 10−13 M ligand were taken
as 100%. (E ) Receptor internalization in HEK-293 cells expressing hκOR
treated with Col or Sal A (0–1 μM) for 30 min at 37 °C; percent internalized
receptors were calculated as described in SI Materials and Methods. (F–H)
HEK-293 cells expressing hκOR were treated for 3 min at 37 °C with either
Col or Sal A (10−13–10−6 M) and phosphorylated levels of ERK1/2 (F), Akt at
S473 (G), or Akt at T308 (H) measured. Data (A–H) represent mean ± SEM;
n = 3–6. *Values obtained with 10 μM ligand. n.d., not detected.
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(IC50 = 0.08 mg/kg), and this effect is desensitized at higher
doses (Fig. 5E). Also, Colly-mediated attenuation of pruritus
can be reversed by the κOR antagonist nor-BNI (Fig. 5F). We
also find that Colly treatment has no effect on animal move-
ment in an open field test (Fig. 5G). These results indicate that
Colly is a novel, high-potency hκOR agonist with behavioral
properties distinct from that of Sal A that taken with its biased
agonistic activity makes it an attractive candidate for further
studies exploring the molecular pharmacology of κOR.
Discussion
Sal A was the first described naturally occurring nonnitrogenous
furyl-δ-lactone diterpene agonist of κOR (18). In this study, we
show that Collys are potent and selective hκOR agonists, thereby
extending the repertoire of naturally occurring furyl-δ-lactone
terpenes that function as κOR ligands. It is interesting to note
that most κOR ligands, particularly Sal A, exhibit nanomolar
affinity for κOR. Interestingly, docking studies using the crystal
structure of hκOR bound to the antagonist JDTic suggest that
different chemotypes of κOR ligands bind to the same pocket
in the receptor (25). We find that epimerization of Colly at C9
reduces agonist binding and signaling. These results suggest that
the C9 position makes significant contributions to full binding
and signaling at hκOR. The generation of novel ligands based on
the Colly structure that could be used in cocrystallization studies
with hκOR would help elucidate how Collys bind to κOR.
An observation in this study is that, although Sal A completely
displaces radiolabeled binding to hκOR Collys, in particular
9-epi-Colly, do not. This partial displacement of radiolabeled bind-
ing could be because (i) Collys exhibit poor solubility in aqueous
solutions such that at high concentrations lesser amounts are
available for displacement of bound radiolabel; (ii) at high con-
centrations, Collys bind to a second site in hκOR functioning as
an allosteric modulator of bound radiolabeled ligand; (iii) the
radiolabeled ligands used in this study stabilize different con-
formations of the receptor some of which are not accessible for
displacement by Collys; and (iv) it is possible that hκOR is com-
plexed with different proteins, and Collys are able to recognize and
bind to hκOR only in some of these complexes. Among these
possibilities the most probable one particularly in the case of 9-epi-
Colly would be poor solubility in aqueous solution. Thus, further
studies are needed to explore in detail how Collys bind to hκOR
in comparison with naloxone, Dip, and U69 and generation of
water-soluble analogs of Collys could help address some of these
questions.
Behavioral studies report that Sal A exhibits antinociceptive
activity (26), is aversive in rodents (24), dose-dependently in-
creases immobility in the forced swim test (27), is anxiolytic in
the elevated plus maze test (28), and can attenuate cocaine-
induced drug seeking behavior (29). In this study, we find that
Colly, like Sal A, exhibits antinociception and is aversive in mice.
However, unlike Sal A, a 2-mg/kg dose of Colly tends to decrease
immobility time in the forced swim test, suggesting that Colly
may exhibit antidepressant activity. Interestingly, evaluation of
the effects of Colly in the open field test suggests that at a dose of
2 mg/kg it tends to be anxiogenic, whereas Sal A has been
reported to be anxiolytic (28). Studies examining the effects of
Sal A on compound 48/80-induced itch behavior (30) reported
low and inconsistent effects in attenuation of scratching behavior.
We find that the Sal A-mediated antipruritic effect on chloroquine-
mediated itch is low and inconsistent (Fig. 5), whereas Colly-
mediated antipruritic effect is consistent and robust (Fig. 5). These
properties make Colly an ideal candidate for further studies ex-
ploring molecular and behavioral properties of κOR, as well as for
the development of novel therapeutics for the treatment of itch
and other κOR-mediated pathologies.
A hallmark characteristic of Sal A is that it is a potent hallu-
cinogen. Thus, administration of vaporized Sal A to human
volunteers leads to intense psychotropic effects including hallu-
cinations, disconnection from external reality, and altered in-
teroceptive abilities (31). To date, it is not known if Collys exhibit
hallucinogenic effects. An extensive web search for information
about the fungus C. maculata did not reveal any reports of hal-
lucinogenic properties: only that the fungus is bitter to taste. If it
holds true that Collys are not hallucinogenic, this would rule out
the involvement of the furyl-δ-lactone motif in the hallucino-
genic effects of Sal A. Structure–activity studies comparing
modifications in Sal A and Colly structures could help elucidate
the motifs required for the hallucinogenic properties. In addi-
tion, it would be important to examine the contribution of biased
signaling toward the differences in the behavioral effects of Sal A
and Colly. Such studies are particularly important given reports
that biased signaling at κOR can distinguish the aversive effects
of κOR agonists from the antinociceptive effects (8). Consistent
with this, studies have shown that, whereas Sal A appears to be
an unbiased ligand based on G-protein activation and β-arrestin
recruitment assays, a structural derivative, RB-64, appears to
exhibit G-protein–biased activity (32). Studies with this com-
pound argue for a contribution of the G-protein pathway in
κOR-mediated analgesia and aversion and of other pathways on
κOR-mediated motor coordination, sedation, and anhedonia
(33). In the present study, we show that Colly exhibits biased
agonistic activity and differs from Sal A in blocking chloroquine-
mediated itch. This observation makes Colly an ideal compound
for further studies. The amenability of the structure of Colly to
modifications provides a platform for generation of analogs, thus
expanding the repertoire of biased κOR ligands; this could help
delineate the signaling pathways in κOR-mediated behaviors and
Table 1. Signaling with collybolides
Ligands
[35S]GTPγS binding AC activity phospho ERK1/2 phospho Akt S473 phospho Akt T308 Internalization
EC50 [M] % Emax* EC50 [M] % Inhibition* EC50 [M] % Emax EC50 [M] % Emax EC50 [M] % Emax EC50 [M] % Emax*
Colly 2 ± 1 E−9 124 ± 2 9 ± 2 E−10 22 ± 2 9 ± 2 E−12 167 ± 11† 2 ± 1 E−10 225 ± 8 1 ± 1 E−10 350 ± 9‡ 5 ± 1 E−10 18 ± 8
9-epi-Colly 3 ± 2 E−10 115 ± 1 4 ± 2 E−6 10 ± 3 4 ± 1 E−9 141 ± 7* 4 ± 2 E−10 160 ± 17 6 ± 2 E−11 190 ± 31 8 ± 3 E−11 79 ± 10
Sal A 2 ± 1 E−10 136 ± 4 9 ± 1E−10 20 ± 2 3 ± 1 E−10 162 ± 17‡ 3 ± 2 E−9 190 ± 19‡ 1 ± 1 E−10 291 ± 3‡ 5 ± 2 E−10 18 ± 5
U69,593 6 ± 2 E−8 132 ± 1 2 ± 1 E−9 30 ± 2 2 ± 1 E−10 274 ± 39‡ 2 ± 1 E−10 156 ± 9 3 ± 2 E−10 271 ± 8 2 ± 1 E−9 15 ± 5
DynA8 2 ± 1 E−10 133 ± 3 2 ± 1 E−9 16 ± 1 ND ND ND ND ND ND 1 ± 1 E−9 26 ± 5
HEK-293 membranes expressing hκOR were subjected to a [35S]GTPγS binding assay (20 μg) or to an adenylyl cyclase (AC) activity assay (2 μg) with κOR
ligands (10−13–10−5 M). HEK-293 cells expressing hκOR (2 × 105 cells per well) were treated with κOR ligands, phosphorylation of ERK1/2, Akt S473, or T308
measured after 3 min or receptor internalized after 30 min. Values obtained at 10−13 M ligand were taken as 100%. Data are mean ± SEM; n = 6. ND,
not done.
*Values obtained with 10 μM ligand concentration.
†Values obtained with 1 nM ligand concentration.
‡Values obtained with 100 nM ligand concentration.
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side effects. In sum, our studies show that collybolides represent
novel κOR selective agonists. These compounds could be
used to further investigate the molecular pharmacology of κOR,
explore the role of κOR in vivo, and develop novel therapeutics
(agonists, antagonists, and partial agonists) that could be clin-
ically used to treat disorders involving the κOR system.
Materials and Methods
Natural Compounds, Materials, and Analytical Data. Sal A was from In Solve
Scientific, Colly and 9-epi-Colly were from the collection of two of the co-
authors (A.C. and J.P.) after their discovery (21) (analytical details in SI Ma-
terials and Methods); 10 mM stock solutions of Sal A, Colly, and 9-epi-Colly in
DMSO were used in all assays. U69,593 (34), Dyn A8, and protease inhibitor
mixture were from Sigma. [3H]Diprenorphine, [3H]Naloxone, [3H]U69,593,
and [35S]GTPγS with specific radioactivities of 42.3, 61.1, 37.4, and 1250 Ci/mmol,
respectively, were from Perkin-Elmer. κOR KO mice brains were a gift from
Charles Chavkin (University of Washington, Seattle).
Cell Culture. HEK-293 or CHO cells were grown in DMEM or F12 media,
respectively, that contained 10% (vol/vol) FBS and penicillin-streptomycin.
Cells were transfected with hμOR, hδOR, or hκOR cDNAs using lipofectamine
as per the manufacturer’s protocol (Invitrogen). Saturation binding as-
says using [3H]Naloxone (0–10 nM) show that the cells express similar
amounts of receptors (874 ± 240 fmol/mg protein for hμOR, 837 ± 171 for
hδOR, and 816 ± 253 for hκOR).
Membrane Preparation. Membranes were prepared from HEK-293 cells
expressing hκOR, hδOR, and hμOR, from cerebral cortex or whole brains of
WT or κOR KO mice as described previously (35).
Receptor Displacement Binding Assays. Glass tubes treated for 10 min with
0.1% (vol/vol) aquaSil-siliconizing fluid in double distilled water were used.
Membranes from HEK-cells expressing hμOR, hδOR, or hκOR (200 μg/tube),
cerebral cortex, or whole brains (100 μg/tube) of WT or κOR KO mice were
incubated with [3H]Diprenorphine, [3H]Naloxone, or [3H]U69,593 (3 nM final
concentration) in the presence of different concentrations (10−13–10−5 M) of
κOR ligands for 2 h at 30 °C as described previously (35, 36). Details of buffers
used are given in SI Materials and Methods.
[35S]GTPγS Binding Assays. Assays were carried out in glass tubes treated as
described above. Membranes (20 μg) were subjected to a [35S]GTPγS binding
assay with κOR ligands (10−13–10−5 M) as described previously (35, 36). nor-
BNI (10 μM) was added 30 min before the assay.
Measurement of Adenylyl Cyclase Activity. Membranes (2 μg) were treated
with 20 μM forskolin in the absence or presence of κOR ligands (10−13–10−5 M)
for 30 min at 37 °C. cAMP levels were determined using the HitHunter cAMP
MEM chemiluminescence detection kit from DiscoveRx.
Measurement of ERK1/2 and Akt Phosphorylation. CHO or HEK-293 cells
expressing hκOR, hμOR, or hδOR (2 × 105 cells per well) were treated with
vehicle or κOR ligands (10−13–10−6 M) for 3 min at 37 °C. ERK1/2 phosphorylation
and Akt phosphorylation at S473 or T308 were measured by Western blot as
previously described (36, 37).
Receptor Internalization. HEK-293 cells expressing hκOR (2 × 105 cells per well)
were incubated at 4 °C for 1 h with 1:1,000 anti-HA antibody to label cell
surface κOR. Cells were treated without or with 100 nM of κOR ligands for
different time intervals (0–120 min) or with different doses (0–1 μM) of κOR
ligands for 30 min at 37 °C. Cells were fixed and cell surface receptors de-
termined by ELISA using 1:1,000 dilution (in PBS containing 1% BSA) of anti-
rabbit IgG coupled to HRP (Vector Laboratories).
Animal Studies. Male C57BL/6J mice, 10–12 wk of age (Jackson Laboratories)
were housed in groups of three to five per cage in a humidity- and tem-
perature-controlled room with a 12-h light/dark cycle (lights on 07:00–19:00
hours) and given free access to food and water throughout the experiment.
Behavioral procedures were according to ethical guidelines/regulations ap-
proved by the Icahn School of Medicine Animal Care and Use Committee.
Animal care and all experimental procedures were in accordance with
guidelines from the National Institutes of Health.
Tail Flick Assay.Mice (7–10/group) were injected i.p. with vehicle [6% (vol/vol)
DMSO in saline], Sal A, or Colly (2 mg/kg), and antinociception was measured
using the tail-flick assay (38).
Conditioned Place Preference/Aversion. Animals (7–10/group) were admin-
istered i.p. with vehicle in one chamber and 8 h later with vehicle/Colly
(2 mg/kg, i.p.) in the other chamber. These injections were repeated for
4 d using an unbiased, counterbalanced design. On the test day (day 6),
animals were placed in the central white chamber, and place preference/
aversion was measured for 20 min. Change in preference (seconds) = time
spent in drug-paired compartment on test day − time spent in this compart-
ment in the preconditioning session.
Forced Swim Test. Mice (7–10/group) were injected i.p. with vehicle or Colly
(2 mg/kg) and placed inside a glass beaker (height 44 cm, diameter 22 cm) filled
with water at a depth of 30 cm, at 25 ± 2 °C, and behavior was recorded for
6 min. Mice were scored blind for the treatment conditions for time spent
immobile.
Elevated Plus Maze. Mice (7–10/group) were injected i.p. with vehicle, Sal A,
or Colly (2 mg/kg) and placed onto the center of the elevated plus maze, and
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Fig. 5. Behavioral effects of collybolide. (A) Mice were administered with
vehicle (Veh), Sal A (Sal), or Colly (Col) (2 mg/kg), and antinociception was
measured at different time intervals using the tail flick assay. Two-way
ANOVA: time, F(2,42) = 1.486, P = 0.238; drug, F(2,21) = 4.199, P = 0.029;
Bonferroni post hoc: *P < 0.05 vehicle vs. Sal A/Col. (B) Forced swim test
with mice administered with Veh or Col (2 mg/kg). (C ) Mice administered
with Veh, Sal, Col (2 mg/kg), or nor-BNI (10 mg/kg) + Col were placed in
the elevated plus maze, and time spent in the open arms was measured.
(D) Mice were administered with Veh or Col (2 mg/kg) for 4 d, and place
preference was measured. t test: *P < 0.05. (E ) Mice were administered
with chloroquine-phosphate (20 mg/kg) in the absence or presence of Sal
or Col (2–2,000 μg/kg), and number of scratches was measured for 15 min.
Veh vs. Col 2,000 μg/kg, unpaired t test: *P < 0.05. (F ) Assessment of the
effect of nor-BNI (10 mg/kg) on Col-mediated attenuation of itch. *P <
0.05; one-way ANOVA. (G) Mice were injected i.p. with Veh, Col (2 mg/kg),
Sal A (2 mg/kg), or nor-BNI (10 mg/kg) + Col (2 mg/kg) 20 min before
subjecting them to the open field test. Data (A–G) represent mean ± SEM;
n = 7–10 mice per group.
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were recorded. Percentage time spent in open arms was used as a measure
of anxiety. A separate set of animals was given nor-BNI (10 mg/kg, i.p.)
20 min before Colly administration.
Open Field.Mice were injected with i.p. with vehicle, Colly (2 mg/kg), Sal A
(2 mg/kg), or nor-BNI (10 mg/kg) + Colly (2 mg/kg) 20 min before the open
field test. Distance traveled (cm) over 10 min was quantified using Ethovision
XT tracking system (Noldus).
Chloroquine-Mediated Itch Behavior. Mice (7–10/group) were injected i.p.
with vehicle (0.9% saline + 2% DMSO), Colly, or Sal A (2–2,000 μg/kg) 10 min
before inducing itch. To induce itch, mice were injected s.c. with chloro-
quine-phosphate (20 mg/kg) into the base of the neck, placed into the re-
cording chamber, and videotaped for 15 min. Total number of scratches in
5-min intervals were scored by experimenters blinded to the drug treat-
ments. A scratch was defined as hind paw movements directed to the site of
injection (30, 39). Another set of animals was evaluated for the effect of nor-
BNI on collybolide-mediated itch attenuation.
Statistical Analysis. Data were analyzed using Prism 6.0 (Graph Pad), and
statistical analysis was carried out using t test or one-way ANOVA.
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